Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

LENZ Therapeutics

Trading 09-02 09:51:26 EDT

5.64

+0.41

+7.74%

High5.66	Low5.21	Vol173.99K
Open5.21	D1 Closing5.23	Amplitude8.60%
Mkt Cap176.32M	Tradable Cap103.65M	Total Shares31.29M
T/O959.57K	T/O Rate0.95%	Tradable Shares18.39M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"LENZ","market":"US","secType":"STK","nameCN":"Therapeutics","latestPrice":5.635,"timestamp":1788357085840,"preClose":5.23,"halted":0,"volume":173988,"delay":0,"changeRate":0.07743785850860407,"floatShares":18393300,"shares":31289969,"eps":-4.13,"marketStatus":"Trading","change":0.405,"latestTime":"09-02 09:51:26 EDT","open":5.21,"high":5.66,"low":5.21,"amount":959574.3200964,"amplitude":0.086042,"askPrice":5.65,"askSize":598,"bidPrice":5.62,"bidSize":346,"shortable":3,"etf":0,"ttmEps":-4.13,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788379200000},"marketStatusCode":2,"adr":0,"listingDate":1624593600000,"exchange":"NASDAQ","adjPreClose":5.23,"preHourTrading":{"tag":"盘前","latestPrice":5.21,"preClose":5.23,"latestTime":"08:13 EDT","volume":216,"amount":1115.4340008,"timestamp":1788351182046,"change":-0.02,"changeRate":-0.003824,"amplitude":0.053537},"postHourTrading":{"tag":"盘后","latestPrice":5.19,"preClose":5.23,"latestTime":"19:48 EDT","volume":1886,"amount":9897.72,"timestamp":1788306504804,"change":-0.04,"changeRate":-0.007648,"amplitude":0.01912},"volumeRatio":5.16675,"impliedVol":2.6963,"impliedVolPercentile":0.9286},"requestUrl":"/m/hq/s/LENZ/tweets","defaultTab":"tweets","newsList":[{"id":"2664811229","title":"Allogene Therapeutics Announces Retirement of Chief Financial Officer Geoffrey Parker","url":"https://stock-news.laohu8.com/highlight/detail?id=2664811229","media":"GlobeNewswire","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664811229?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:30","pubTimestamp":1788352200,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (Allo","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355132/0/en/allogene-therapeutics-announces-retirement-of-chief-financial-officer-geoffrey-parker.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4139","BK4007","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819046","title":"Acrivon Therapeutics to Present at the 2026 Cantor Global Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819046","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819046?lang=en_us&edition=fundamental","pubTime":"2026-09-02 20:00","pubTimestamp":1788350400,"startTime":"0","endTime":"0","summary":"WATERTOWN, Mass., Sept.  02, 2026 (GLOBE NEWSWIRE) -- Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biotechnology company discovering and developing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3355075/0/en/acrivon-therapeutics-to-present-at-the-2026-cantor-global-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HCSG","XBI","LU0029874061.USD","LENZ","BK4588","LU0128526141.USD","XLV","LABU","BK4539","BK4007","BK4137","BK4139","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664819124","title":"TScan Therapeutics Restructures to Focus on Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664819124","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664819124?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:59","pubTimestamp":1788350350,"startTime":"0","endTime":"0","summary":"The latest update is out from TScan Therapeutics ( ($TCRX) ). On September 2, 2026, TScan Therapeutics announced a strategic reorganization that sh...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/tscan-therapeutics-restructures-to-focus-on-solid-tumors?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/tscan-therapeutics-restructures-to-focus-on-solid-tumors?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","TCRX","BK4539","BK4139","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664815050","title":"TScan Therapeutics Announces Strategic Reorganization to Focus on in vivo Cell Therapy for Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2664815050","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664815050?lang=en_us&edition=fundamental","pubTime":"2026-09-02 19:00","pubTimestamp":1788346800,"startTime":"0","endTime":"0","summary":"Advances two in vivo-engineered TCR-T candidates for solid tumors to IND-enabling studies with plans to initiate Phase 1 development in Q4 2027 Reports updated data from Cohort C of the Phase 1 ALLOHA","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354974/0/en/tscan-therapeutics-announces-strategic-reorganization-to-focus-on-in-vivo-cell-therapy-for-solid-tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BK4007","BK4539","LENZ","EES"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664159448","title":"Goldman Sachs Sticks to Their Hold Rating for Ocumension Therapeutics (1477)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664159448","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664159448?lang=en_us&edition=fundamental","pubTime":"2026-09-02 18:56","pubTimestamp":1788346587,"startTime":"0","endTime":"0","summary":"In a report released today, from Goldman Sachs maintained a Hold rating on Ocumension Therapeutics, with a price target of HK$7.92. The word on The...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-ocumension-therapeutics-1477-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/goldman-sachs-sticks-to-their-hold-rating-for-ocumension-therapeutics-1477-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664997828","title":"Aptabio Therapeutics Plans Seoul NDR to Deepen R&D Dialogue with Institutions","url":"https://stock-news.laohu8.com/highlight/detail?id=2664997828","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664997828?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:21","pubTimestamp":1788330080,"startTime":"0","endTime":"0","summary":"Aptabio Therapeutics, Inc. ( ($KR:293780) ) has provided an update. Aptabio Therapeutics, Inc., a biotechnology company focused on research and dev...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/aptabio-therapeutics-plans-seoul-ndr-to-deepen-rd-dialogue-with-institutions?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/aptabio-therapeutics-plans-seoul-ndr-to-deepen-rd-dialogue-with-institutions?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4585","FHLC","FWD","BK4588","IEIH","BK4007","JDOC","LNGR","XT","BK4139","AGNG","DARP","RSPH","IBB","BK4539","SYNB","BBP"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664996128","title":"Retail Employees Super Fund Exits Substantial Holding in PYC Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664996128","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664996128?lang=en_us&edition=fundamental","pubTime":"2026-09-02 14:15","pubTimestamp":1788329749,"startTime":"0","endTime":"0","summary":"An announcement from PYC Therapeutics Limited ( ($AU:PYC) ) is now available. Retail Employees Superannuation Pty Ltd, acting as trustee of the Ret...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/retail-employees-super-fund-exits-substantial-holding-in-pyc-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/retail-employees-super-fund-exits-substantial-holding-in-pyc-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","BK4139","BK4539","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664999896","title":"Prescient Therapeutics Hits Dose Optimization Review Milestone in Cancer Drug Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664999896","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664999896?lang=en_us&edition=fundamental","pubTime":"2026-09-02 13:38","pubTimestamp":1788327489,"startTime":"0","endTime":"0","summary":"Prescient Therapeutics  reached the pre-specified enrollment threshold for its first planned dose optimization committee review in a phase 2a study of its PTX-100 drug candidate in relapsed or refractory cutaneous T-cell lymphoma, according to a Wednesday filing with the Australian bourse.The company said 10 evaluable patients, or those who have completed four cycles of treatment, are now enrolled in each of the study's two dosing arms for 20 evaluable patients in total.The first dose optimization committee review remains on track for December, and enrollment in the study continues globally toward a full target of 40 evaluable patients.Cutaneous T-cell lymphoma is a type of immune system cancer where abnormal white blood cells migrate to and attack the skin.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","PTX.AU","BK4007","BK7067","BK4539","LENZ","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664508978","title":"Kazia Therapeutics is Maintained at Buy by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2664508978","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664508978?lang=en_us&edition=fundamental","pubTime":"2026-09-01 23:06","pubTimestamp":1788275160,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/KZIA/analyst-ratings","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664285768","title":"BioMarin Completes Acquisition of Dutch Biotech Alesta Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2664285768","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664285768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:26","pubTimestamp":1788272819,"startTime":"0","endTime":"0","summary":"BioMarin Pharmaceutical ( ($BMRN) ) just unveiled an announcement. BioMarin Pharmaceutical Inc. has completed the acquisition of Dutch biotech comp...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/biomarin-completes-acquisition-of-dutch-biotech-alesta-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","BK4139","BK4539","BK4007","LENZ","XBI","BK4585","BK4588","XBIX","NVIB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664385768","title":"Kazia Therapeutics price target raised to $40 from $34 at BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2664385768","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664385768?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:20","pubTimestamp":1788272414,"startTime":"0","endTime":"0","summary":"BTIG raised the firm’s price target on Kazia Therapeutics (KZIA) to $40 from $34 and keeps a Buy rating on the shares after the company announced n...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/kazia-therapeutics-price-target-raised-to-40-from-34-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/kazia-therapeutics-price-target-raised-to-40-from-34-at-btig-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664522518","title":"HighTide Therapeutics Grants Performance-Linked Share Options and Awards","url":"https://stock-news.laohu8.com/highlight/detail?id=2664522518","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664522518?lang=en_us&edition=fundamental","pubTime":"2026-09-01 22:14","pubTimestamp":1788272067,"startTime":"0","endTime":"0","summary":"An announcement from Hightide Therapeutics Inc ( ($HK:2511) ) is now available. HighTide Therapeutics has granted 2,040,450 share options and 306,7...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/hightide-therapeutics-grants-performance-linked-share-options-and-awards?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/hightide-therapeutics-grants-performance-linked-share-options-and-awards?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","LENZ","BK4007","BK4539"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664497851","title":"Press Release: BioMarin Announces Close of the Alesta Therapeutics Acquisition","url":"https://stock-news.laohu8.com/highlight/detail?id=2664497851","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664497851?lang=en_us&edition=fundamental","pubTime":"2026-09-01 21:05","pubTimestamp":1788267900,"startTime":"0","endTime":"0","summary":"Acquisition adds ALE1, a potential first oral therapy for hypophosphatasia to clinical pipelineSAN RAFAEL, Calif., Sept. 1, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","BK4232","IE0002270589.USD","IE00B19Z3B42.SGD","R","IE00B19Z3581.USD","IE00B7SZLL34.SGD","BK4223","BK4566","BK4539","BK4194","BK4139","BK4022","BMRN","HPP","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859245","title":"Analyst Maintains Buy on Tenax Therapeutics as Subgroup Data Support Drug’s Potential; Price Target Reiterated at $4","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859245","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859245?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:36","pubTimestamp":1788266182,"startTime":"0","endTime":"0","summary":"In a report released yesterday, Angela Qian from Canaccord Genuity maintained a Buy rating on Tenax Therapeutics, with a price target of $4.00. Ang...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-tenax-therapeutics-as-subgroup-data-support-drugs-potential-price-target-reiterated-at-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/analyst-maintains-buy-on-tenax-therapeutics-as-subgroup-data-support-drugs-potential-price-target-reiterated-at-4-ratings-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664940859","title":"Kazia Therapeutics Reports Preclinical Tumor Reduction in Colorectal Cancer Study","url":"https://stock-news.laohu8.com/highlight/detail?id=2664940859","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664940859?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:30","pubTimestamp":1788265806,"startTime":"0","endTime":"0","summary":"Kazia Therapeutics (KZIA) said Tuesday that data showed its paxalisib therapy significantly reduced tumor burden and the total amount of cancer in the body by 52% in a preclinical model of microsatell","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","BK4139","BK4539","KZIA","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664859981","title":"Ocumension Therapeutics' Application for Ocular Inflammation Drug Accepted in China","url":"https://stock-news.laohu8.com/highlight/detail?id=2664859981","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664859981?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:26","pubTimestamp":1788265560,"startTime":"0","endTime":"0","summary":"Ocumension Therapeutics'  application for the registration of dexamethasone intraocular suspension was accepted by China's National Medical Products Administration.The product is indicated for the treatment of postoperative ocular inflammation, according to a Tuesday Hong Kong bourse filing.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LENZ","BK1574","BK4007","BK4539","BK4139","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664562148","title":"Metagenomi Therapeutics, Inc. to Present at the Wells Fargo 21st Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664562148","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664562148?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"EMERYVILLE, Calif., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Metagenomi Therapeutics, Inc. (Nasdaq: MGX) (the “Company”), an in vivo genome editing company capitalizing on its proprietary technologies to c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354046/0/en/metagenomi-therapeutics-inc-to-present-at-the-wells-fargo-21st-annual-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B19Z3B42.SGD","LU2236285917.USD","LU0868494617.USD","XLV","LABU","LU0029864427.USD","LU2361044865.SGD","LU1668664300.SGD","IE000M9KFDE8.USD","LU0310800965.SGD","LU0211327993.USD","LU0251142724.SGD","FTXO","LU0208291251.USD","LU0477156953.USD","LU1074936037.SGD","LU0314106906.USD","HCSG","LU0106831901.USD","TFNS","XBI","LU0130517989.USD","LU0048573561.USD","LU0256863811.USD","LU1363072403.SGD","MGX","LU0708994859.HKD","BK4007","BK4501","LU1267930490.SGD","LU0128525929.USD","LU0787776722.HKD","KBWB","LU0128526141.USD","LU0072461881.USD","LU0128525689.USD","LU0130102774.USD","LU0175139822.USD","LENZ","LU0149725797.USD","LU0417517546.SGD","BK4559","LU0211328371.USD","LU0971096721.USD","BK4539","IYF","LU2361044949.HKD","LU0154236417.USD","PGF","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664485625","title":"Relmada Therapeutics to Participate at the Wells Fargo 21st Annual Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2664485625","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664485625?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"CORAL GABLES, Fla., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD, “Relmada” or the “Company”), a clinical-stage biotechnology company advancing innovative therapies for","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354047/0/en/relmada-therapeutics-to-participate-at-the-wells-fargo-21st-annual-healthcare-conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0162691827.USD","LABU","IE0002270589.USD","LU0052756011.USD","BK4582","BK4137","LU0175139822.USD","LU0868494708.USD","IE00B19Z3B42.SGD","LU0320765489.SGD","LU0314106906.USD","LU0477156953.USD","LU0640476718.USD","XLV","LU0128525689.USD","LU0128526141.USD","LU0128525929.USD","LENZ","LU0648001328.SGD","LU1280957306.USD","LU0310799852.SGD","LU2361044949.HKD","LU0211327993.USD","LU0072461881.USD","LU0029864427.USD","BK4139","KBWB","PGF","LU0149725797.USD","FTXO","HCSG","LU2361045086.USD","IE00B19Z3581.USD","LU0256863811.USD","LU1267930490.SGD","LU1069347547.HKD","LU1894683264.USD","LU1035773651.USD","LU0154236417.USD","LU2461242641.AUD","BK4588","LU0942090050.USD","IE00B7SZLL34.SGD","BK4539","LU1668664300.SGD","TFNS","LU0742534661.SGD","XBI","IYF","LU1267930573.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664243856","title":"Dianthus Therapeutics to Participate in Three Investor Conferences During September","url":"https://stock-news.laohu8.com/highlight/detail?id=2664243856","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664243856?lang=en_us&edition=fundamental","pubTime":"2026-09-01 20:00","pubTimestamp":1788264000,"startTime":"0","endTime":"0","summary":"NEW YORK and WALTHAM, Mass., Sept.  01, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354082/0/en/dianthus-therapeutics-to-participate-in-three-investor-conferences-during-september.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4539","BK4007","BK4139","LENZ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664855444","title":"Stoke Therapeutics and Biogen Announce Presentations of Clinical Data from Studies of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome, at the 16th European Epilepsy Congress (EEC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2664855444","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664855444?lang=en_us&edition=fundamental","pubTime":"2026-09-01 19:30","pubTimestamp":1788262200,"startTime":"0","endTime":"0","summary":"–4-year data from the Phase 1/2a open-label extension (OLE) studies support the potential disease-modifying effects of zorevunersen– –Improvements in cognition and behavior sustained through 4 years, ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/09/01/3354025/0/en/stoke-therapeutics-and-biogen-announce-presentations-of-clinical-data-from-studies-of-zorevunersen-an-investigational-medicine-for-the-treatment-of-dravet-syndrome-at-the-16th-euro.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","EPV","BIIB"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://ir.lenz-tx.com","stockEarnings":[{"period":"1week","weight":0.1199},{"period":"1month","weight":-0.0132},{"period":"3month","weight":-0.2539},{"period":"6month","weight":-0.5663},{"period":"1year","weight":-0.8646},{"period":"ytd","weight":-0.6731}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.137955},{"month":2,"riseRate":0.4,"avgChangeRate":0.032476},{"month":3,"riseRate":0.2,"avgChangeRate":-0.143415},{"month":4,"riseRate":0.4,"avgChangeRate":-0.0217},{"month":5,"riseRate":0.2,"avgChangeRate":-0.134259},{"month":6,"riseRate":0.6,"avgChangeRate":-0.009929},{"month":7,"riseRate":0.5,"avgChangeRate":0.033083},{"month":8,"riseRate":0.333333,"avgChangeRate":0.01095},{"month":9,"riseRate":0.666667,"avgChangeRate":0.023036},{"month":10,"riseRate":0.6,"avgChangeRate":-0.067546},{"month":11,"riseRate":0.6,"avgChangeRate":-0.005451},{"month":12,"riseRate":0.4,"avgChangeRate":-0.038411}],"exchange":"NASDAQ","name":"Therapeutics","nameEN":"Therapeutics"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Therapeutics,LENZ,Therapeutics股票,Therapeutics股票老虎,Therapeutics股票老虎国际,Therapeutics行情,Therapeutics股票行情,Therapeutics股价,Therapeutics股市,Therapeutics股票价格,Therapeutics股票交易,Therapeutics股票购买,Therapeutics股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Therapeutics(LENZ),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Therapeutics(LENZ) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction